Drug Development

A groundbreaking clinical trial is testing whether a common bone-strengthening drug can 'unmask' and eliminate the hidden HIV reservoir, a critical barrier to a cure.

Venture builder Foresite Labs hires AstraZeneca's AI leader, Dr. Jorge Reis-Filho, in a strategic move that signals a new era for AI-driven company creation.

A novel therapy that disarms rather than kills a deadly superbug offers a glimpse of a post-antibiotic future for patients with a debilitating lung disease.

A Breakthrough T1D grant for Greenstone Bio isn't just funding; it's a major signal validating a new R&D paradigm using AI and bio-digital twins.

For families facing the grim prognosis of GM2 gangliosidoses, a new alliance offers a glimmer of hope, revealing the strategic interplay of academia and industry.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.

The dermatology giant posts strong revenue but dips in profit, channeling funds into high-impact acquisitions and R&D for underserved skin conditions.

Coultreon Biopharma's strategic hire of Dr. Prista Charuworn signals a major push to advance its novel SIK3 inhibitor in the crowded autoimmune market.

A Boston biotech with Korean roots just went public in Seoul. Its goal: to repair the body's smallest blood vessels, a market Merck has already bet billions on.

Beyond beta-blockers, a new class of targeted therapies is revolutionizing hypertrophic cardiomyopathy care, sparking a fierce corporate race for market dominance.

In a strategic pivot, Skye Bioscience acquires Redx Pharma, creating Fibrx Therapeutics—a new Nasdaq-listed player armed with $125M and a bold plan.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Fannin Partners secures key grants to advance its Raptamer therapy for a rare pediatric cancer, highlighting a funding model vital for high-risk innovation.

With a new CEO, a leaner budget, and crucial data on the horizon for its brain and obesity drugs, Neumora is navigating a pivotal phase of growth.

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.